Home > Insider Trading > Filing (0001104659-22-073622)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1368151	Vincent Capponi	C/O Cytosorbents Corporation 305 College Road East Princeton NJ 08540	President And Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-06-21	2,000	$1.80	443,545	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a 10b5-1 trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 10,100 RSUs granted on March 15, 2018, (ii) 17,900 RSUs granted on February 24, 2017, (iii) 54,000 RSUs granted on June 7, 2016 and (iv) 125,000 RSUs granted on April 8, 2015;
(continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and
(continued from footnote 3) (c) 215,806 shares of Common Stock owned by the reporting person, inclusive of the 2,000 shares purchased on June 21, 2022 and reported on this Form 4.